WallStSmart

Astrana Health Inc (ASTH)vsUniversal Health Services Inc (UHS)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Universal Health Services Inc generates 371% more annual revenue ($18.11B vs $3.84B). UHS leads profitability with a 8.4% profit margin vs 1.1%. UHS trades at a lower P/E of 7.0x. UHS earns a higher WallStSmart Score of 72/100 (B).

ASTH

Buy

56

out of 100

Grade: C

Growth: 10.0Profit: 4.5Value: 4.7Quality: 4.5
Piotroski: 1/9Altman Z: 2.10

UHS

Strong Buy

72

out of 100

Grade: B

Growth: 6.0Profit: 7.0Value: 6.0Quality: 6.0
Piotroski: 5/9Altman Z: 2.76
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for ASTH.

UHSSignificantly Overvalued (-24.0%)

Margin of Safety

-24.0%

Fair Value

$186.49

Current Price

$174.83

$11.66 premium

UndervaluedFair: $186.49Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ASTH3 strengths · Avg: 9.3/10
Revenue GrowthGrowth
48.5%10/10

Revenue surging 48.5% year-over-year

EPS GrowthGrowth
110.5%10/10

Earnings expanding 110.5% YoY

Price/BookValuation
2.3x8/10

Reasonable price relative to book value

UHS3 strengths · Avg: 9.7/10
P/E RatioValuation
7.0x10/10

Attractively priced relative to earnings

Price/BookValuation
1.4x10/10

Reasonable price relative to book value

Return on EquityProfitability
20.2%9/10

Every $100 of equity generates 20 in profit

Areas to Watch

ASTH4 concerns · Avg: 3.0/10
Market CapQuality
$1.89B3/10

Smaller company, higher risk/reward

Return on EquityProfitability
3.8%3/10

ROE of 3.8% — below average capital efficiency

Profit MarginProfitability
1.1%3/10

1.1% margin — thin

Operating MarginProfitability
3.5%3/10

Operating margin of 3.5%

UHS0 concerns · Avg: 0/10

No major concerns identified

Comparative Analysis Report

WallStSmart Research

Bull Case : ASTH

The strongest argument for ASTH centers on Revenue Growth, EPS Growth, Price/Book. Revenue growth of 48.5% demonstrates continued momentum.

Bull Case : UHS

The strongest argument for UHS centers on P/E Ratio, Price/Book, Return on Equity. PEG of 1.14 suggests the stock is reasonably priced for its growth.

Bear Case : ASTH

The primary concerns for ASTH are Market Cap, Return on Equity, Profit Margin. A P/E of 46.4x leaves little room for execution misses. Thin 1.1% margins leave little buffer for downturns.

Bear Case : UHS

No major red flags identified for UHS, but monitor valuation.

Key Dynamics to Monitor

ASTH profiles as a hypergrowth stock while UHS is a value play — different risk/reward profiles.

UHS carries more volatility with a beta of 1.06 — expect wider price swings.

ASTH is growing revenue faster at 48.5% — sustainability is the question.

UHS generates stronger free cash flow (216M), providing more financial flexibility.

Bottom Line

UHS scores higher overall (72/100 vs 56/100). Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Astrana Health Inc

HEALTHCARE · MEDICAL CARE FACILITIES · USA

Astrana Health, Inc., Inc., a physician-centric technology-powered healthcare management company, provides medical care services in the United States. The company is headquartered in Alhambra, California.

Universal Health Services Inc

HEALTHCARE · MEDICAL CARE FACILITIES · USA

UnitedHealth Group Incorporated is an American for-profit multinational managed healthcare and insurance company based in Minnetonka, Minnesota. It offers health care products and insurance services.

Visit Website →

Want to dig deeper into these stocks?